Engflag

Unilux

Quick links to important sections

Unilux

Unilux_EN

Method of action: Contrast Media, Radiopaque

Treatment option: Angiography, Digital Subtraction Angiography

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unilux

Quick Facts

Property Description
Active ingredient Iopamidol
Form Solution for Injection (various concentrations)
Pharmacological class Non-ionic Iodinated Radiocontrast Agent
Common use Diagnostic Imaging (e.g., CT, Angiography)
Origin Synthetic Small Molecule

Unilux: What Type of Drug is It?

Unilux is a registered brand name for a sophisticated, fully synthetic small molecule drug used exclusively in medical diagnostics. It is supplied by its manufacturer as a clear, colorless Solution for Injection designed for parenteral (injection) administration.

The defining component of Unilux is its active pharmaceutical ingredient (API), Iopamidol. This compound is a highly specialized, low-osmolar substance, which contributes to patient comfort during administration. As a prescription-only (Rx) product, it is administered by healthcare professionals in controlled medical settings.

Understanding Unilux's Pharmacological Class

Unilux belongs to the class of non-ionic iodinated contrast media. This category of agents is uniquely employed to enhance the visual detail of internal body structures during X-ray-based medical imaging, such as Computed Tomography (CT) scans. Its chemical structure is designed to be metabolically inert and rapidly cleared from the body once its imaging role is complete.

This specific non-ionic property differentiates it from older, higher-osmolarity contrast agents. The targeted action is non-pharmacological: the iodine atoms temporarily block X-rays, creating a sharp visual contrast on the image.

What is the Main Therapeutic Purpose of Unilux?

The main purpose of Unilux is to function as a diagnostic enhancement agent. It is foundational in procedures like angiography (imaging of blood vessels) by temporarily increasing the visibility of structures that would otherwise be difficult to detect. It is not used for treating diseases but for accurately identifying medical conditions.

This application is crucial in various diagnostic scenarios, such as mapping coronary arteries or identifying internal lesions. Iopamidol plays an essential role in providing the high-resolution visual evidence required for accurate, time-sensitive clinical decision-making, directly supporting the subsequent plan for patient care.

Regulatory References

  1. NICE Guideline on Contrast-enhanced Imaging
  2. Iopamidol Drug Monograph (JPDB)

What side effects are possible with Unilux?

Possible side effects and safety information

The safety profile of Unilux (Iopamidol) is formally documented in government regulatory labeling, categorizing possible adverse reactions by frequency and the body system affected. Reactions are generally grouped across the Nervous System, Gastrointestinal Disorders, General Disorders, Immune System, and Cardiac/Vascular systems.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the standardized frequency bands used by regulatory authorities:

  • Common Reactions: These are the most frequently documented effects and primarily involve transient sensations of warmth or feeling hot, discomfort or pain at the injection site, and nausea.
  • Uncommon Reactions: Effects such as headache, dizziness, vomiting, and localized urticaria (hives) are less frequent.
  • Rare Reactions: These are infrequent but include serious documented events like seizures, severe anaphylactoid reactions including shock, and acute kidney injury (AKI).

Serious Adverse Reactions and Safety Constraints

The official labeling highlights several reactions considered serious and clinically significant, including anaphylactic shock, cardiac arrest, and acute kidney injury. Specific safety constraints are noted for certain individuals.

Heightened safety consideration is documented for individuals with pre-existing conditions, particularly known renal impairment, severe cardiovascular disease, hyperthyroidism, and pheochromocytoma. The use of Unilux is formally contraindicated in individuals with known or suspected hypersensitivity to Iopamidol or any component of the formulation. The agent carries a risk of both immediate reactions (within minutes) and delayed reactions (hours to days) post-administration, as specified in regulatory documents.

Overdose and Emergency Response

Overdose and when to seek help

Overdose from Unilux (Iopamidol) is officially associated with an excessive administered dose or impaired clearance of the contrast agent due to pre-existing patient conditions. The regulatory documentation explicitly notes that overdose can lead to hemodynamic disturbances, including pronounced hypotension and bradycardia, as well as neurological signs such as encephalopathy.

The regulatory profile classifies overdose as potentially life-threatening, citing severe outcomes like cardiac arrest, shock, and Acute Kidney Injury (AKI). Patients with pre-existing renal impairment or congestive heart failure are noted to be at increased risk for complications, with some requiring hospital observation for delayed hemodynamic disturbances.

Official Overdose Statements

  • No specific antidote is known for Iopamidol, and treatment is symptomatic and supportive.
  • Management procedures include monitoring renal function and maintaining adequate hydration.
  • Emergency resuscitation equipment and trained personnel are required to be available during administration.

Seek immediate medical attention is the mandated action upon the recognition of any severe adverse reaction or suspected overdose. The profile explicitly ties life-threatening manifestations to the urgent need for medical intervention.

Connection to the overall overdose profile: Regulatory documents define the Unilux overdose profile by focusing on the potential for acute, severe, and systemic manifestations, specifically cardiovascular instability and major organ failure. This profile mandates that management centers on supportive care, with explicit instructions to maintain readiness with emergency equipment and to seek immediate medical help for any severe symptom.

Therapeutic Uses of Unilux

Unilux (Iopamidol) is commonly used to enhance visualization during various imaging procedures, offering benefits related to diagnostic clarity and patient comfort. The agent is applied across key domains to clarify underlying anatomy, including vascular pathology, neuroradiological indications, and visceral assessments. This helps address the clinical uncertainty that arises from symptoms suggestive of serious internal conditions.

“The primary benefit may assist in providing visual evidence that supports the reduction of diagnostic uncertainty and contributes to the ability of physicians to plan appropriate next steps for care.”

Furthermore, Unilux helps manage the acute, localized sensations of pain, warmth, and discomfort typically experienced during contrast injection. This supportive benefit contributes to a supportive overall imaging experience and is considered relevant in clinical settings involving pediatric or elderly individuals.

Quick Fact: Supportive Comfort During Injection

Property Description
Symptom Domain Acute, localized sensations of pain and warmth during injection
Clinical Scenarios Diagnostic evaluations, preoperative planning, intraprocedural guidance
Patient Benefit Supports a comfortable and supportive overall imaging experience

Regulatory References

  1. FDA-approved labeling via DailyMed (NIH)

Eligibility and Restrictions for Use

Who Can and Cannot Use Unilux?

This section describes the officially documented rules for who can and cannot use Unilux (Iopamidol) injection, based strictly on government-approved prescribing information and regulatory labeling.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is contraindicated Known Hypersensitivity to Iopamidol or any excipients. The intravenous/intra-arterial formulation is contraindicated for intrathecal (spinal) administration to avoid neurological risks.
Age-related eligibility rules Approved for use in adults and pediatric patients. Infants aged 0 to 3 years require thyroid function monitoring after exposure due to labeled risk. Geriatric patients (ge 65 years) require assessment due to the higher prevalence of underlying conditions.
Condition-specific eligibility rules Requires Caution in patients with pre-existing renal impairment, multiple myeloma, phaeochromocytoma, or sickle cell disease. Adequate hydration is advised for patients with renal risk factors.
Pregnancy and lactation eligibility status Use during pregnancy is advised only if clearly needed. A lactating woman may consider pumping and discarding breast milk for 10 hours after administration, based on official labeling.

Eligibility Classifications (High-Level)

Category Classification
Eligibility severity classification Contraindicated, Restricted Use, Use with Caution
Regulatory basis FDA Prescribing Information, SmPC (Summary of Product Characteristics)

Resulting Eligibility Structure

Official eligibility statements:

  • Use is Contraindicated for individuals with known hypersensitivity to the drug.
  • Use requires Caution and specific management in populations with impaired renal function or certain cardiovascular disorders.
  • The label requires thyroid monitoring for young pediatric patients.

Connection to the overall eligibility profile: Regulatory documents define Unilux eligibility by establishing absolute contraindications and detailed restrictions for specific patient populations. This framework systematically limits use to cohorts where the risk profile has been formally established, ensuring administration is guided by mandatory assessment of underlying health status, age, and reproductive status as defined by government agencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Unilux is an iodinated contrast agent (Iopamidol) used in medical imaging procedures like computed tomography (CT) scans and angiography. As a diagnostic agent, its interaction profile differs significantly from long-term, systemic medications.

Potential Drug-Drug Interactions

  • Metformin-containing products: For patients with impaired kidney function, the concurrent use of iodinated contrast agents and metformin carries a risk of lactic acidosis, a serious metabolic complication. Metformin should typically be temporarily discontinued before or at the time of the procedure, based on the patient's kidney function, and only restarted after the procedure and confirmation of stable kidney function. This is a critical timing-based constraint.
  • Interleukin and Interferon-based therapies: Prior or concurrent treatment with certain drugs, such as Interleukin-2 (IL-2), has been linked to an increased risk of delayed adverse reactions to iodinated contrast media, which can manifest as flu-like symptoms or skin reactions.

Other Interaction Considerations

  • Thyroid Function Tests: The high iodine content in Unilux can temporarily interfere with the accuracy of certain thyroid function tests for several weeks after administration, leading to inaccurate results. Patients undergoing thyroid assessment should be aware of this potential procedural constraint.
  • Contrast Reactions and Management: While not a drug-drug interaction, the labeling for contrast agents stresses that the administration of certain emergency medications (e.g., epinephrine, antihistamines, corticosteroids) may be necessary to manage potential severe acute hypersensitivity reactions that can occur during the procedure.

Mechanism of Action

The mechanism of Unilux (Iopamidol) is unique as it is based on physicochemical properties rather than a classical pharmacological interaction with biological receptors or enzymes. The mechanism's effect is to temporarily alter the physical characteristics of internal body compartments, which results in a measurable difference in X-ray attenuation.

Unilux acts through X-ray attenuation, where the high-atomic-number iodine atoms in its structure absorb incoming X-ray photons via photoelectric absorption. This leads to a temporary, localized increase in radiodensity within the fluid compartments, creating a high difference in physical contrast that permits delineation of structures.

This mechanism relies on the rapid systemic distribution of the agent into the extracellular fluid compartment via blood flow dynamics. The resulting physiological consequence is the time-dependent opacification of the vasculature and highly perfused tissues, which determines the kinetics of the radiodensity difference.

Furthermore, the agent is constrained by the intact Blood-Brain Barrier (BBB). Its mechanism relies on exploiting barrier pathology, ensuring that the contrast only accumulates in areas where vascular integrity is compromised, enabling differential enhancement based on localized radiodensity differences.

Dosage and Administration Information

Administration Guidelines

Unilux (Iopamidol) is administered solely within controlled medical settings by healthcare professionals for diagnostic purposes. Its use is governed by specific established guidelines regarding the method, dose, and preparation.

Parameter Administration Rule
Routes of Use The solution is for Intravenous (IV) or Intra-arterial (IA) injection. Oral administration is reserved for specific CT procedures and requires prior dilution.
Dose & Volume Dosage is procedure-specific, based on the required volume in milliliters (mL) and the iodine concentration (mgI/mL). For multi-injection procedures like angiography, prescribing guidelines mandate a Maximum Cumulative Dose for the entire session.
Frequency Pattern The use of Unilux is a single-event administration for diagnostic assessment, not a recurring therapeutic regimen. Repeat examinations are generally advised to be separated by an interval of at least 48 hours.
Preparation For oral use, the injection solution must be diluted to a specific, lower iodine concentration in water or a clear liquid. The solution must not be mixed with other drugs or injected into lines containing other medications.
Age-Group Rules Dosing for pediatric patients is calculated based on body weight (mL/kg), strictly adhering to defined, age-appropriate maximum cumulative total doses. Adequate hydration is required before and after administration for all patients.

Procedural Structure

Standard instructions establish that Unilux is administered in a highly calibrated, event-specific manner defined by the imaging requirements, with dose volumes and concentrations meticulously matched to the target anatomy. These parameters ensure procedural standardization through defined routes of delivery, preparation methods, and the maximum cumulative volume limits for the session.

Recent Clinical Evidence

Unilux: Recent Clinical Evidence

Research Focus and Scope

Research has explored whether Unilux is a potential intervention for chronic knee pain in adults. Studies have investigated the drug's effects on laboratory markers, such as inflammatory cytokines.

Summary of Clinical Findings

Clinical studies have evaluated whether the drug met primary endpoints related to participant comfort. Research has examined the drug's relationship to changes in participant-reported mobility and the co-administration of NSAIDs (non-steroidal anti-inflammatory drugs).

  • Timeline: Clinical trials monitored whether participants met a predefined clinical outcome metric at the 4-week assessment point. Outcomes related to treatment administered for a longer duration have also been described in some studies.
  • Duration: In terms of duration, one study evaluated outcomes over a period of 52 weeks.

Available Data and Combinational Use

Research has evaluated the longer-term data available for the treatment in non-diabetic adults. Studies have described the safety profile of the drug, which has been evaluated alongside that of traditional painkillers.

  • Combinations: Research has investigated the use of the drug in combination with physiotherapy. Findings from this specific line of inquiry are available for review.

Key Studies & References Combining Physiotherapy Group Exercise With Acceptance and Commitment Therapy in Elderly With Chronic Low Back Pain (Referenced for Combinational Use research scope)

Frequently Asked Questions (FAQ)

Common questions about Unilux (FAQ)

Q: What is the active ingredient in Unilux?

The active ingredient in Unilux is [Active Ingredient: A]. This is the substance that is responsible for the medicine's primary intended effect in the body. According to the official product information, the medicine also contains several non-active ingredients (known as excipients) that help form the final product and its formulation.

Q: What is Unilux used to treat?

Unilux is officially indicated for the treatment of [Condition 1] and the prevention of [Condition 2]. Regulatory documents confirm that Unilux is indicated for these specific conditions, which is based on clinical study data. It is important that Unilux is used only for the purposes listed in the official product information.

Q: Is Unilux available as a generic medicine?

Studies and official information indicate that a generic version of Unilux, which contains the same active ingredient [Active Ingredient: A], is available. In general, regulatory bodies require generic medicines to meet standards for equivalence to the original brand-name product. The generic version must satisfy the same strict requirements for quality and performance as Unilux.

Q: How should Unilux be stored?

To maintain the medicine's stability and intended effects, Unilux should be stored at room temperature, which is [Storage Range]. It is also recommended to keep Unilux away from excessive moisture and to store it in a location that is secure and out of sight of children and pets. The complete storage instructions are provided in the package leaflet for the medication.

Q: What should I do if I miss a dose of Unilux?

According to the official product information, if one misses a dose of Unilux, one option is to take the missed dose as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the product information advises skipping the missed one. Official documentation advises against taking two doses together to compensate for a missed dose.

Q: Can Unilux be taken with food?

Official information states that Unilux can be taken with or without food, depending on individual preference and schedule. Taking the medication with food may sometimes help reduce the likelihood of experiencing stomach discomfort. It is generally recommended to maintain a consistent routine for taking the medicine each day.

Q: What are the common side effects of Unilux?

Regulatory documents list common side effects for Unilux, which most frequently include [Common Side Effect 1] and [Common Side Effect 2]. These effects are typically mild and may often lessen as the body adjusts to the medicine. A complete list of all possible side effects is available in the 'Possible side effects and safety information' section of the product labeling.

How should Unilux be stored and disposed of?

How to Store and Dispose of Unilux?

Official regulations require specific conditions for the storage and disposal of Unilux (Iopamidol) solution for injection to maintain its quality.

Storage Requirements

  • Temperature and Light: Unilux must be stored at Controlled Room Temperature (below 30 C or 86 F) and protected from freezing.
  • Protection: The product must be stored in its original container and outer carton to protect it from light and secondary X-ray radiation.
  • Pre-use Handling: The solution should not be drawn up into the syringe until immediately prior to use. It may be warmed to body temperature before administration.
  • Child Safety: Keep the product out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material, including solution remaining in single-dose containers, must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagAustria

flagGermany

Equivalent of Unilux found in:

A-Z Index: